In a significant development, Syndax Pharmaceuticals Inc. has announced a new clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback